Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Chinese Journal of Experimental Traditional Medical Formulae ; (24): 74-79, 2021.
Article in Chinese | WPRIM | ID: wpr-906208

ABSTRACT

Objective:To explore the anti-hepatoma effect of compound <italic>Phylanthus urinaria</italic> Ⅱ ( CPU Ⅱ) by inhibiting the expression of the long non-coding RNA (lncRNA) colon cancer associated transcript-1 (CCAT1) and restoring the expression of microRNA let-7a. Method:Real-time fluorescence quantitative polymerase chain reaction (PCR) was used to detect the expression of lncRNA CCAT1 in normal liver cells (LO2 cells) and hepatocellular carcinoma HepG2 cells, and the differences in expression between these two types of cells were compared. The methylthiazolyl tetrazolium(MTT) assay was used to detect the proliferation of HepG2 cells after treatment with different concentrations of CPU Ⅱ and 5-fluorouracil(5-FU) for 24, 48 and 72 h. Hepatocellular carcinoma HepG2 cells were cultured <italic>in vitro </italic>and set into three gropes: cell control group, CPU Ⅱ low-dose group (0.8 g·L<sup>-1</sup>) and high-dose group (1.6 g·L<sup>-1</sup>). Real-time PCR was used to detect the mRNA expression of lncRNA CCAT1, microRNA let-7a and its target genes high mobility group protein A2(HMGA2), and N-RAS in each grope. Western blot was used to detect the protein expression of HMGA2, and Cyclin D<sub>1</sub> in each grope. Result:As compared with LO2 cells, expression of lncRNA CCAT1 in HepG2 cells was significantly up-regulated (<italic>P</italic><0.05). Results of MTT assay showed that the 50% inhibiting concentration(IC<sub>50</sub>)<sub> </sub>of CPU Ⅱ and 5-FU on hepatocellular carcinoma HepG2 cells was 1.649, 0.044 648 g·L<sup>-1 </sup>respectively. As compared with the control group, CPU Ⅱ high-and low-dose groups (1.6, 0.8 g·L<sup>-1</sup>) significantly inhibited the proliferation of HepG2 cells (<italic>P</italic><0.05), and the effect was most remarkable in CPU Ⅱ high-dose group (<italic>P</italic><0.05). The results of Real-time PCR showed that as compared with control group, the expression of lncRNA CCAT1 mRNA was significantly inhibited in CPU Ⅱ high-and low-dose groups (<italic>P</italic><0.05), and the expression of microRNA let-7a mRNA was obviously up-regulated in high-dose group (<italic>P</italic><0.05), but the expression of HMGA2 mRNA in CPU Ⅱ high-and low-dose groups as well as the expression of N-RAS mRNA in CPU Ⅱ low-dose group were down-regulated (<italic>P</italic><0.05). Western blot results showed that as compared with the cell control group, the protein expression of HMGA2 and Cyclin D<sub>1</sub> in CPU Ⅱ high-and low-dose groups (1.6, 0.8 g·L<sup>-1</sup>) was significantly down-regulated (<italic>P</italic><0.05). Conclusion:CPU Ⅱ can inhibit the expression of lncRNA CCAT1, recover the expression of microRNA let-7a, and suppress the mRNA and protein expression of related downstream target genes in hepatoma cells line HepG2, thereby inhibiting the proliferation of hepatocellular carcinoma cells and exerting anti-hepatocellular carcinoma effect.

2.
Chinese Journal of Preventive Medicine ; (12): 316-319, 2012.
Article in Chinese | WPRIM | ID: wpr-292476

ABSTRACT

<p><b>OBJECTIVE</b>To examine the state of incubation period and survival time of former commercial plasma donors (FCPDs) infected with HIV.</p><p><b>METHODS</b>All objects infected with HIV were from Hebei province and found from general investigation for FCPDs in 1995. The infector cohort by 142 cases was used to estimate incubation period. In the infector cohort, the time which infectors entered the cohort was their infection time, which was the middle value of the origin date, which was January 1, 1995. The onset of AIDS was defined as an outcome event. End point of observation was Dec 31, 2010. There were 192 months in all from beginning to end. The AIDS cohort by 57 cases was used to estimate the survival of the patients. In the patient cohort, the time of AIDS onset was defined as the time entering the cohort, and death of AIDS was defined as an outcome event. The cumulative incidence ratio, cumulative mortality, illness intensity and mortality intensity were analyzed through Kaplan-Meier.</p><p><b>RESULTS</b>During the observation period, 123 cases of 142 infectors developed into AIDS, the cumulative incidence was 86.42% (123/142) and the intensity was 8.53/100 person-years and the median time of incubation period was 112.0 months (95%CI: 108.8 - 115.2). The death dates of 57 patients were from 1 to 24 months after onset. The cumulative mortality was 100%, and the intensity was 250.66/100 person-years and the median survival time was 3.0 months (95%CI: 1.8 - 4.2). It was estimated that the median time was 115.0 months (9.6 years) from infection to death.</p><p><b>CONCLUSION</b>The median times of incubation and median survival time were 112.0 and 3.0 months, respectively.</p>


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Young Adult , Blood Donors , Cohort Studies , HIV , Physiology , HIV Infections , Epidemiology , Mortality , Virology , Incidence , Retrospective Studies , Survival Rate , Virus Latency
SELECTION OF CITATIONS
SEARCH DETAIL